FibroGen, Inc. (NASDAQ:FGEN) Short Interest Update

FibroGen, Inc. (NASDAQ:FGEN) was the target of a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 5,300,000 shares, an increase of 79.7% from the February 13th total of 2,950,000 shares. Based on an average daily volume of 3,330,000 shares, the days-to-cover ratio is presently 1.6 days. Currently, 5.4% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on FGEN. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of FibroGen in a research note on Thursday, February 20th. StockNews.com began coverage on shares of FibroGen in a research report on Friday. They set a “hold” rating for the company.

FibroGen Trading Up 2.9 %

Shares of FGEN traded up $0.01 during trading hours on Friday, reaching $0.44. 1,204,677 shares of the company’s stock traded hands, compared to its average volume of 2,324,187. FibroGen has a 12 month low of $0.18 and a 12 month high of $2.80. The stock has a market cap of $44.27 million, a PE ratio of -0.36 and a beta of 0.82. The firm’s 50 day simple moving average is $0.51 and its 200-day simple moving average is $0.43.

Institutional Investors Weigh In On FibroGen

Hedge funds have recently bought and sold shares of the stock. FMR LLC raised its position in shares of FibroGen by 21.8% during the 3rd quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 68,569 shares in the last quarter. Geode Capital Management LLC lifted its stake in FibroGen by 3.1% during the third quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock worth $433,000 after purchasing an additional 32,884 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of FibroGen by 430.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock worth $668,000 after purchasing an additional 1,358,194 shares in the last quarter. Franklin Street Advisors Inc. NC lifted its position in FibroGen by 100.0% in the 4th quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 100,000 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in FibroGen by 80.4% in the fourth quarter. Renaissance Technologies LLC now owns 1,358,712 shares of the biopharmaceutical company’s stock worth $719,000 after buying an additional 605,572 shares in the last quarter. 72.71% of the stock is currently owned by institutional investors.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.